Par Drugs And Chemicals Limited has informed the Exchange regarding 'Outcome of Board Meeting Dated 07.08.2025'.
PAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Par Drugs and Chemicals' board, meeting on August 7, 2025, approved the unaudited standalone financial results for Q1 FY26 (quarter ended June 30, 2025), reviewed by statutory auditors Sarupria Somani & Associates with an unqualified limited review report. Revenue from operations rose to Rs. 2,604.64 lakh, up about 15% from Rs. 2,260.56 lakh in Q1 FY25, while total income climbed to Rs. 2,788.31 lakh. Profit after tax jumped to Rs. 332.81 lakh (from Rs. 253.31 lakh YoY), a ~31% rise, pushing EPS to Rs. 2.70 (vs Rs. 2.06 YoY). The company also renewed its Rs. 161 lakh banking facility with Kotak Mahindra Bank with no change in limit, and confirmed zero pending investor complaints.
Strong YoY earnings growth in both revenue and profit signals healthy operational momentum for this API manufacturer, likely to be viewed positively by shareholders. The flat banking limit renewal is routine and not material.